Show simple item record

dc.contributor.authorHoyle, Alex P
dc.contributor.authorAli, S
dc.contributor.authorJames, N
dc.contributor.authorParker, C
dc.contributor.authorCook, A
dc.contributor.authorAttard, G
dc.contributor.authorChowdhury, S
dc.contributor.authorCross, W
dc.contributor.authorDearnaley, D
dc.contributor.authorde Bono, J
dc.contributor.authorGilson, C
dc.contributor.authorGillessen, Silke
dc.contributor.authorJones, R
dc.contributor.authorMatheson, D
dc.contributor.authorMason, M
dc.contributor.authorRitchie, A
dc.contributor.authorRussell, M
dc.contributor.authorParmar, M
dc.contributor.authorSydes, M
dc.contributor.authorClarke, Noel W
dc.date.accessioned2019-04-29T09:48:56Z
dc.date.available2019-04-29T09:48:56Z
dc.date.issued2018en
dc.identifier.citationHoyle AP, Ali SA, James ND, Parker CC, Cook AD, Attard G, et al. Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. Ann Oncol. 2018;29(suppl_8):722.en
dc.identifier.doi10.1093/annonc/mdy424.033en
dc.identifier.urihttp://hdl.handle.net/10541/621758
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy424.033en
dc.titleEffects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUro-Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record